Use of the COMPASS (n = 195) and Hartwig (n = 113) validation mPDAC cohorts was an important step to mitigating sample size limitations, and our finding of molecular similarities shared between cholangiocarcinoma and KRAS wildtype mPDAC was able to be validated in this way. The gene discussed is KRAS; the disease is cholangiocarcinoma.